摘要
目的:采用网状Meta分析方法系统评价益气活血类口服中成药治疗冠心病心绞痛的有效性及安全性。方法:检索Embase、PubMed、CNKI、万方数据库中关于益气活血类中成药治疗冠心病心绞痛的随机对照试验(RCT),检索时间范围为建库至2019年12月。通过Stata15.1软件以临床总有效率、心电图改善率以及心绞痛改善率、发作频率与持续时间为结果指标进行网状Meta分析并绘图。结果:最终纳入51项RCTs,共5144例患者,包括9种益气活血类中成药。结果显示:临床总有效率,排序为麝香保心丸>血栓心脉宁片>灯盏生脉胶囊>参桂胶囊>通心络胶囊>通脉养心丸>养心氏片>麝香通心滴丸>脑心通胶囊;心电图改善情况,排序为通脉养心丸>养心氏片>灯盏生脉胶囊>麝香通心滴丸>麝香保心丸>通心络胶囊>参桂胶囊>脑心通胶囊;减少心绞痛发作频率与持续时间排序分别为:灯盏生脉胶囊>麝香通心滴丸>通心络胶囊>血栓心脉宁片>麝香保心丸>通脉养心丸>参桂胶囊>脑心通胶囊;通脉养心丸>血栓心脉宁片>通心络胶囊>麝香通心滴丸>灯盏生脉胶囊>麝香保心丸。结论:益气活血类中成药联合常规西药治疗冠心病心绞痛具有明显优势,可优先考虑麝香保心丸、灯盏生脉胶囊与通脉养心丸。
Objective:To evaluate the efficacy and safety of oral Chinese patent medicine for nourishing qi and activating blood in the treatment of angina pectoris of coronary heart disease.Methods:The randomized controlled trials(RCTs)on Chinese patent medicine for nourishing qi and activating blood in the treatment of angina pectoris of coronary heart disease were retrieved from databases including Embase,PubMed,CNKI,and Wanfang,and the time range for searching was from the establishment of databases to December 2019.The total clinical effective rate,rate of improved(electrocardiogram,ECG),rate of alleviated angina,attack frequency and duration of angina attack were considered as the outcome indicators for network meta analysis and mapped with stata15.1 software.Results:A total of 51 RCTs were included with 5144 cases and 9 kinds of patent Chinese medicine for nourishing qi and activating blood.The results showed that Shexiang Baoxin pill had the highest clinical total effective rate followed by Xueshuan Xinmaining tablet,Dengzhan Shengmai capsule,Shengui capsule,Tongxinluo capsule,Tongmai Yangxin pill,Yangxin tablet,Shexiang Tongxin drop pill,and Naoxintong capsule.In terms of ECG,Tongmai Yangxin pill showed the best improvement rate,followed by Yangxin tablet,Dengzhan Shengmai capsule,Shexiang Tongxin drop pill,Shexiang Baoxin pill,Tongxinluo capsule,Shengui capsule,and Naoxintong capsule.In addition,for reducing attack frequency,Dengzhan Shengmai capsule was the best followed by Shexiang Tongxin drop pill,Tongxinluo capsule,Xueshuan Xinmaining tablet,Shexiang Baoxin pill,Tongmai Yangxin pill,Shengui capsule and Naoxintong capsule.While Tongmai Yangxin pill was most effective in reducing the duration of angina followed by Xueshuan Xinmaining tablet,Tongxinluo capsule,Shexiang Baoxin pill,Dengzhan Shengmai capsule,and Shexiang Tongxin drop pill.Conclusion:Chinese patent medicine for nourishing qi and activating blood combined with Western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be chosen with priority.
作者
王卓溪
班纪芳
李柔乐
王铁风
客蕊
WANG Zhuo-xi;BAN Ji-fang;LI Rou-le;WANG Tie-feng;KE Rui(The First Clinical Medical College,Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China;The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China)
出处
《海南医学院学报》
CAS
2021年第11期845-854,共10页
Journal of Hainan Medical University
基金
黑龙江省应用技术研究与开发计划(GY2019YF0237)
全国中医药创新青年人才培训项目(14061190007)。
关键词
冠心病心绞痛
口服中成药
网状Meta分析
随机对照试验
Angina pectoris of coronary heart disease
Oral patent Chinese medicine
Network-meta analysis
Randomized controlled trial
